RenovoRx (RNXT) Stock Price, News & Analysis

Company Overview

RenovoRx, Inc. is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors. By leveraging a patented catheter design, the system enables localized drug perfusion through arterial infusion, potentially enhancing tumor uptake of chemotherapeutic agents. RenovoRx has also entered strategic collaborations to advance its clinical programs, including licensing arrangements for development and commercialization in select international markets.

Headquartered in Little Silver, New Jersey, RenovoRx conducts its clinical development activities through a network of investigative sites across the United States. The company’s management team comprises seasoned professionals with experience in interventional oncology, medical device development and regulatory affairs. As a Nasdaq-listed entity trading under the symbol RNXT, RenovoRx continues to advance its pipeline toward pivotal studies with the goal of offering new treatment options for patients with limited therapeutic alternatives.

Key Stats

• Today's Range: $1.16 to $1.24
• 50-Day Range: $0.87 to $1.40
• 52-Week Range: $0.75 to $1.69
• Volume: 888,134 shs
• Average Volume: 182,754 shs
• Market Capitalization: $42.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.50
• Consensus Rating: Buy

RenovoRx Stock Analysis - MarketRank™

RenovoRx scored higher than 38% of companies evaluated by MarketBeat, and ranked 712th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

RenovoRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

RenovoRx has a consensus price target of $7.50, representing about 541.0% upside from its current price of $1.17.

Amount of Analyst Coverage

RenovoRx has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for RenovoRx are expected to decrease in the coming year, from ($0.40) to ($0.46) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of RenovoRx is -3.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of RenovoRx is -3.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

RenovoRx has a P/B Ratio of 6.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.38% of the float of RenovoRx has been sold short.

Short Interest Ratio / Days to Cover

RenovoRx has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in RenovoRx has recently increased by 54.84%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

RenovoRx does not currently pay a dividend.

Dividend Growth

RenovoRx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.38% of the float of RenovoRx has been sold short.

Short Interest Ratio / Days to Cover

RenovoRx has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in RenovoRx has recently increased by 54.84%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for RenovoRx this week, compared to 1 article on an average week.

Search Interest

5 people have searched for RNXT on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

MarketBeat Follows

2 people have added RenovoRx to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, RenovoRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,300.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 9.13% of the stock of RenovoRx is held by insiders.

Percentage Held by Institutions

Only 3.10% of the stock of RenovoRx is held by institutions.

RNXT Stock Analysis - Frequently Asked Questions

How have RNXT shares performed this year?

RenovoRx's stock was trading at $1.29 on January 1st, 2025. Since then, RNXT stock has decreased by 9.3% and is now trading at $1.17.

How were RenovoRx's earnings last quarter?

RenovoRx, Inc. (NASDAQ:RNXT) posted its quarterly earnings results on Thursday, August, 14th. The company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). The business had revenue of $0.42 million for the quarter, compared to analysts' expectations of $0.25 million.
Read the conference call transcript.

When did RenovoRx IPO?

RenovoRx (RNXT) raised $18 million in an IPO on Thursday, August 26th 2021. The company issued 1,800,000 shares at a price of $9.00-$11.00 per share. Roth Capital Partners and Maxim Group LLC acted as the underwriters for the IPO.

Who are RenovoRx's major shareholders?

Top institutional shareholders of RenovoRx include AWM Investment Company Inc. (5.11%), Geode Capital Management LLC (0.97%), Corsair Capital Management L.P. (0.26%) and Northwestern Mutual Wealth Management Co. (0.20%). Insiders that own company stock include Ramtin Agah, Shaun Bagai, Laurence Marton, Ron Kocak and Angela Nelms.
View institutional ownership trends.

How do I buy shares of RenovoRx?

Shares of RNXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of RenovoRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that RenovoRx investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), Bakkt (BKKT), NIO (NIO) and Phunware (PHUN).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/10/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RNXT
• CIK: 1574094
• Web: www.renovorx.com
• Phone: 650-284-4433
• Fax: 650-397-4433
• Employees: 6
• Year Founded: N/A

Price Target and Rating

• Average Price Target for RenovoRx: $7.50
• High Price Target: $12.00
• Low Price Target: $3.00
• Potential Upside/Downside: +527.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.81 million
• Net Margins: N/A
• Pretax Margin: -1,610.88%
• Return on Equity: -120.68%
• Return on Assets: -89.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.61
• Quick Ratio: 8.61

Sales & Book Value

• Annual Sales: $40 thousand
• Price / Sales: 1,094.92
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.19 per share
• Price / Book: 6.29

Miscellaneous

• Outstanding Shares: 36,650,000
• Free Float: 33,300,000
• Market Cap: $43.80 million
• Optionable: Not Optionable
• Beta: 1.24